These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19390535)

  • 1. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
    Saruta T; Hayashi K; Ogihara T; Nakao K; Fukui T; Fukiyama K;
    Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
    Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
    Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
    Nakao K; Hirata M; Oba K; Yasuno S; Ueshima K; Fujimoto A; Ogihara T; Saruta T;
    Hypertens Res; 2010 Jun; 33(6):600-6. PubMed ID: 20379187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
    Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
    Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical implications from the results of the CASE-J extension].
    Yasuno S; Fujimoto A; Ueshima K
    Nihon Rinsho; 2012 Mar; 70(3):519-27. PubMed ID: 22514936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
    Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
    Liu J; Yasuno S; Oba K; Konda M; Ichihara C; Kitao H; Kuwabara Y; Ueshima K
    J Hypertens; 2018 Sep; 36(9):1921-1928. PubMed ID: 29750680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
    London G; Schmieder R; Calvo C; Asmar R
    Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related differences in the effects of antihypertensive therapy on left ventricular hypertrophy in high-risk patients with hypertension-candesartan antihypertensive survival evaluation in Japan subanalysis.
    Ogihara T; Fujimoto A; Ueshima K; Nakao K; Saruta T
    J Am Geriatr Soc; 2011 Jan; 59(1):180-1. PubMed ID: 21226700
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
    Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
    J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
    Koyanagi R; Hagiwara N; Yamaguchi J; Kawada-Watanabe E; Haruta S; Takagi A; Ogawa H;
    J Cardiol; 2013 Oct; 62(4):217-23. PubMed ID: 23778009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
    Yamada H; Suga N; Maeda K; Kimura Y; Miura N; Futenma A; Imai H
    Arzneimittelforschung; 2010; 60(2):64-70. PubMed ID: 20329653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
    Shiga T; Kasanuki H; Hagiwara N; Sumiyoshi T; Honda T; Haze K; Takagi A; Kawana M; Origasa H; Ogawa H;
    Blood Press; 2010 Dec; 19(6):359-65. PubMed ID: 20491606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.